Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. - Wikidata - wikimedia - TriplyDB

Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

http://www.wikidata.org/entity/Q30844786

about

Inflammatory bowel disease surgery in the biologic era Optimal management of steroid-dependent ulcerative colitis Optimizing biologic treatment in IBD: objective measures, but when, how and how often?Promising biological therapies for ulcerative colitis: A review of the literature Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis.Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease.Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.New treatment strategies for ulcerative colitis.Maintenance therapy options for ulcerative colitis.Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target.Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases.Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.The economics of adalimumab for ulcerative colitis.The biologics of ulcerative colitis.Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.Update on the Use of Biologic Therapy in Ulcerative Colitis.Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis.Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis.Biological therapy increases the health-related quality of life in patients with inflammatory bowel disease in a clinical setting.Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study.Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Serum Amyloid A as a Surrogate Marker for Mucosal and Histologic Inflammation in Patients with Crohn's Disease.The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.The functional outcome and factors influencing the quality of life after ileal pouch anal anastomosis in patients with ulcerative colitis.Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.Granulocyte-Monocyte Apheresis as an Adjuvant Therapy to Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis.Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab.Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores.Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors.Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.Mucosal Healing in Ulcerative Colitis: A Comprehensive Review.

P2860

Q26745627-03A1CB41-F303-4771-A743-0AD690ACED73 Q26773203-57136652-3B3A-4C8E-AEB0-461FE6A25B62 Q26775064-F991C542-D3C9-4FA1-A343-3A69B32C3AF1 Q26776139-2A594246-9711-404E-97F1-8E4F8E72D584 Q26801119-616A7950-51AF-459D-B38D-7B8AA488A325 Q28070298-0E43644C-0700-41D6-B2FF-B49A862FAF3B Q35937632-74CB05C7-9972-43E3-BCBB-6F7DF67934AC Q37342575-9D6171B4-B677-4843-BFA0-6C9DC8AC25A3 Q37656048-7A9C355B-881D-4F46-AFC2-01577DBC1534 Q38293774-1C6DC901-278F-4CA6-9128-7BA936A64B80 Q38365426-5CAB7789-FB8A-422E-889C-F2BE3390721D Q38670811-9A0B78F9-62B3-49FC-B284-B248A1C8C56D Q38848140-E608FDD0-169E-43B2-A04A-55608E33B3FB Q38892066-634258E4-BC2C-46B8-9D63-908A81E03CA8 Q38895960-34F66165-37B9-428D-8A41-2356176ADB4F Q38943959-5AF25550-74C0-486A-A0EF-0BA8EE7E5AF7 Q38947390-F4E821D5-9F8D-4087-9D35-764EA4B5D353 Q39024280-071CF2F7-557B-4463-BCC9-FB00D2A39078 Q39037681-3EB3554F-9F7B-49D9-8144-D5A21B9411F9 Q39077823-B45200CE-19D4-4938-8272-7CD61E3ACA06 Q39102244-D259BA98-4FCC-4B71-9A1F-18E3C6BEB0BC Q39251794-53D350BA-EC07-4C60-94E8-C2146B0E7AE4 Q39538749-66380AE5-7E27-488A-8657-DE5788019E6A Q40046590-F1781C12-8D4D-425D-BB5B-7202CC7DA3A9 Q40078937-E780D0D3-D699-4FCC-93AA-E1B44C68D030 Q41520678-6D1C9084-8ECD-44AB-9F20-76AFAC29F935 Q42280471-AB23A884-1E7B-4276-A72C-5FB18B275998 Q42651996-FE04F1C9-B990-4F3B-BB6C-08779D99E445 Q45992381-82F73FA1-3103-4DB5-8F11-8FE92B136B4C Q47109861-EA41D67A-6F8A-4828-98CE-4573493B4D1D Q47194470-5B12A1B3-4F0E-4A62-9FFE-5CC77978F958 Q47857757-B0047C50-2650-43C7-8A3F-4C44B3C49C36 Q48136341-A98D705A-B576-4C58-83E0-7B65BB3531E4 Q48265479-2C4A1DDE-CC2A-49E9-BD02-EE731DD5CCA0 Q48360596-1A63E298-2673-4484-A55B-052F3EC7FE23 Q49500732-3CC8DE5D-16D5-4D97-A09E-9C6C5C7F664D Q50205262-8E3208E9-C9C7-4D85-AFDB-0CEF6D2EF0FC Q50224633-60513C69-3B54-453A-AD19-4901E19990D7 Q51647910-1A4C3125-0A3D-4949-8781-8946C3B5F21B Q53815697-5EA0BD1A-E169-4103-8291-45628343FDE9

P2860

Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

http://www.wikidata.org/entity/Q30844786

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Four-year maintenance treatmen ...... : Data from ULTRA 1, 2, and 3.

@ast

Four-year maintenance treatmen ...... : Data from ULTRA 1, 2, and 3.

@en

type

label

Four-year maintenance treatmen ...... : Data from ULTRA 1, 2, and 3.

@ast

Four-year maintenance treatmen ...... : Data from ULTRA 1, 2, and 3.

@en

prefLabel

Four-year maintenance treatmen ...... : Data from ULTRA 1, 2, and 3.

@ast

Four-year maintenance treatmen ...... : Data from ULTRA 1, 2, and 3.

@en

P1433

Q30844786-542D1A44-2265-4BFD-9FB7-FD9FEB13A701

P1476

Q30844786-C38AAB78-C8EA-4EFF-AAA9-837A17C07F11

P2093

Q30844786-0F5B48C6-90E2-4226-A2D0-F73F477DBD43

Q30844786-1E1D9F08-AF32-4010-AA6E-7A5CE1A231B1

Q30844786-5C855709-92C8-46D8-9C61-F065F6E661F5

Q30844786-7247E650-5A86-4446-B6A5-0AB382B06A1E

Q30844786-7D4760B0-5357-4485-90DE-F4A425048510

Q30844786-7D49AA93-4309-424E-8436-D5DFE1DB738E

Q30844786-9B5DA136-1F5F-4A29-BA68-9CD20EB311AF

Q30844786-A9B874A7-7090-4EC6-855F-A275C75A280A

Q30844786-B0563D09-46B0-4A15-A7AB-81ACB5F021C2

Q30844786-E007FEA5-2D53-4AA7-8B77-14E322D8A40E

P2860

Q30844786-148942A1-BBCA-4A4F-83EF-F56D3190D40F

Q30844786-1B3CD0AE-07F8-4266-A909-C510058CBD68

Q30844786-2DEAE83B-6665-4D6A-ABD9-4D6D6EACA801

Q30844786-2E44FCEF-9D85-426B-A325-04531E0DF825

Q30844786-3E076364-3423-4D35-9A07-10D4E5858CAF

Q30844786-698C24F6-3D53-405D-8A4A-F0513946B7CD

Q30844786-81D140A4-878C-49EC-A6F7-877C8376A62B

Q30844786-D0C4D751-0555-47C4-A323-D56E61D3F90E

Q30844786-D432970E-3D42-4233-A688-599FB6433CA3

Q30844786-E493A4BE-1689-47D1-92AC-26688328F4C2

P304

Q30844786-7259C663-3936-481E-BEAF-08869FC3480D

P31

Q30844786-F375A1B1-3DD1-4C43-B4FF-2090DB97E831

P356

Q30844786-0F78E222-BC99-4CDE-9E21-66B2DC51B81B

P407

Q30844786-48786252-55C1-4FD7-B0BA-8C129A4638CA

P433

Q30844786-8EB42046-1AAF-4AD9-A5D2-4B9E5253C980

P478

Q30844786-85B8D32C-BDF6-4BD7-BCEA-89746222A6EC

P50

Q30844786-1C0C7C1A-708E-4858-A970-E937904AC4EC

Q30844786-2EF583E6-7031-478F-B256-BDE82639F857

Q30844786-774AF41C-C46A-4654-8E4C-21F8F6A2E3C4

P577

Q30844786-618F048F-A2C3-4CB4-B8B2-D0C221ED246A

P5875

Q30844786-393EE5B8-1B70-4720-A6B4-C73573F689C0

P698

Q30844786-5FE537E5-9910-4609-86EE-F059B4EAD5A2

P921

Q30844786-A4A5BC65-ED1F-4B45-A5F5-AE1AC37FA452

P932

Q30844786-CE464665-8D74-4A40-A97C-3127153E2523

P356

P1433

The American Journal of Gastroenterology

P1476

Four-year maintenance treatmen ...... : Data from ULTRA 1, 2, and 3.

@en

P2093

Andreas Lazar

http://www.w3.org/2001/XMLSchema#string

Anne M Robinson

http://www.w3.org/2001/XMLSchema#string

Bidan Huang

http://www.w3.org/2001/XMLSchema#string

Douglas C Wolf

http://www.w3.org/2001/XMLSchema#string

Martha Skup

http://www.w3.org/2001/XMLSchema#string

Martina Kron

http://www.w3.org/2001/XMLSchema#string

Remo Panaccione

http://www.w3.org/2001/XMLSchema#string

Roopal B Thakkar

http://www.w3.org/2001/XMLSchema#string

Subrata Ghosh

http://www.w3.org/2001/XMLSchema#string

Walter Reinisch

http://www.w3.org/2001/XMLSchema#string

P2860

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

Adalimumab safety in global clinical trials of patients with Crohn's disease.

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.

The role of TNFalpha in ulcerative colitis.

Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.

One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

P304

1771-1780

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJG.2014.242

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Frédéric Colombel

William Jeffery Sandborn

Brian G. Feagan

P577

2014-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267749424

http://www.w3.org/2001/XMLSchema#string

P698

25155227

http://www.w3.org/2001/XMLSchema#string

P921

P932

4223868

http://www.w3.org/2001/XMLSchema#string